Bausch + Lomb Corp. announced June 30 that it will acquire XIIDRA, a treatment for dry eye disease (DED), from Novartis for up to $2.5 billion. Bausch + Lomb Chairman and CEO Brent Saunders said ...

Founded in 1853, Bausch + Lomb has a portfolio of 400 products spanning eye care, contact lenses, ophthalmic pharmaceuticals, ophthalmic surgical devices, and instruments, as well as over-the ...

Bausch + Lomb says Xiidra and Meibo will complement each other, targeting different parts of the dry eye disease cycle. Xiidra is small molecule that binds to LFA-1, a protein on the surface of ...

VAUGHAN, Ontario& HEIDELBERG, Germany---- Bausch+ Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, and Novaliq GmbH, a biopharmaceutical ...

Anyone seeking to report adverse effects should contact Bausch + Lomb at 800-338-2020, option 1, or submit a report to the FDA’s MedWatch program (800-332-1088 to request a form).

To report issues, contact Bausch + Lomb Customer Service at 1-800-338-2020, option 1, or submit a report to FDA’s MedWatch program. Saleen Martin is a reporter on USA TODAY's NOW team.

Bausch + Lomb Corporation (NYSE:BLCO; TSX:BLCO), a global eye health company, has been navigating a complex market landscape characterized by both promising opportunities and significant ...

Bausch + Lomb Showcases Eye Care Innovations May 28, 2024 — 10:35 am EDT Written by TipRanks Canadian Newsdesk for TipRanks -> ...

March 27 (Reuters) - Bausch + Lomb (BLCO.TO), opens new tab said on Thursday it will recall some of its implantable eye lenses after receiving reports of complications, the cause of which could ...

Bausch + Lomb drug Miebo is now FDA approved as a new treatment for dry eye disease. Unlike many products that rewet the eye, Miebo is designed to address one of the factors that leads to dry eyes.